Haas Jason
Haas Jason's purchase track record
Haas Jason has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2026 | ODTX | $20K | +28.9% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Odyssey Therapeutics to Present OD-001 Data at UEG Week 2026. Odyssey Therapeutics announced that it will present additional Phase 2a induction data for its drug OD-001 in ulcerative colitis at the UEG Week 2026 conference. This upcoming presentation provides new clinical information on the company's lead candidate. The stock is currently trading near its 52-week low, with an average analyst target price of $35.75.
Transaction History
| LGND | ▲ Buy | Option Exercise | 6,138 | $316K | 8/12/2026 | View on chart |
| LGND | ▼ Sell | Open Market | 7,138 | $2.1M | 8/12/2026 | View on chart |
| LGND | ▲ Buy | Option Exercise | 3,000 | $155K | 6/12/2026 | View on chart |
| LGND | ▲ Buy | Option Exercise | 1,000 | $52K | 6/12/2026 | View on chart |
| LGND | ▼ Sell | Open Market | 3,000 | $765K | 6/12/2026 | View on chart |
| LGND | ▼ Sell | Open Market | 3,461 | $886K | 6/12/2026 | View on chart |
| LGND | ▲ Buy | Grant | 836 | $0 | 6/5/2026 | View on chart |
| ODTX | ▲ Buy | Open Market | 1,000 | $20K | 5/8/2026 | View on chart |
| LGND | ▲ Buy | Grant | 1,209 | $0 | 6/6/2025 | View on chart |
| LGND | ▲ Buy | Grant | 1,252 | $0 | 6/14/2024 | View on chart |
| LGND | ▲ Buy | Grant | 1,142 | $0 | 6/9/2023 | View on chart |
| LGND | ▲ Buy | Grant | 1,750 | $0 | 6/29/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript. Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.